Return to: Medical News

Next Gen Immuno-Oncology Congress-USA will discuss advancements in cancer immunotherapy, clinical development of immune checkpoint inhibitors and neoantigen-based immunotherapy.

MarketsandMarkets is proud to announce the Next Gen Immuno-Oncology Congress USA to be held on 21st and 22nd June 2018 in Philadelphia. The congress aims to bring academicians, researchers and scientists from research institutes pharmaceutical, bio-pharmaceutical and biotechnology companies to address the latest updates in development of CAR-T cell therapy, neoantigen-based and microbiome-derived immunotherapy and new paradigms in immune checkpoint inhibitors.

The two-day, three-stream congress will also focus on various combination strategies, pre-clinical and translational immune-oncology developments, updates in cellular and viral therapies, vaccines development and personalized immunotherapy. This gathering of pharma/biopharma and academia professionals working in the field of Immuno-Oncology will highlight key topics like Neoantigen in personalized Cancer Immunotherapy, Immune Checkpoint Inhibitors and Combinations (PD-1, PD-L1, PD-L4), Preclinical and Translational Immuno-Oncology Developments (Preclinical models for Immune checkpoint modulators), Neoantigen Discovery by Next-Generation Sequencing, Biomarkers and Cancer Vaccines, CAR-T cell therapy, Dendritic Cell Therapy, Microbiome in Cancer Immunotherapy (Targets and Challenges), Oncolytic viruses, Tumour associated Macrophages as treatment in IO, Technologies for personalized TCR engineered cancer immunotherapies and Tumour microenvironment.

The first day of the congress will emphasis on cellular therapy, immune checkpoint inhibitors, Developments in CAR-T cell therapy and combinational therapies with presentations from NIH - USA, GSK, Gritstone Oncology, Agenus, Incyte, University of Connecticut, and University of Pennsylvania.

Whereas the day 2 of the conference will be more focussed on cancer immunotherapies and personalised immunotherapies with presentations talking about Precision Immunology for targeted therapy, Biomarkers in Cancer Immunotherapy, neoantigens in cancer immunotherapy, clinical development of ICI combinations and more. Highlight of the conference will be the presentation of Stefan Gluck, Vice President, Global Medical Affairs at Celgene, USA on the day 2. HE will presenting on studies in pancreatic cancer with IO compounds shading a light on new concepts and data about the novel studies in Pancreatic cancer and their susceptibility to ICI in combination with Chemotherapy and other IO agents.

Apart from Dr. Gluck, the conference will also feature some of the great mind of Immuno-Oncology industry such as [add few important speaker names with their organisations] who will be delivering keynote presentations, brainstorming panel discussions and case studies will give the stakeholders an opportunity to discuss and understand the uses faced and comes up with solutions for the same.

The congress will be attended by professionals working in pharma, biotech and leading institutes in USA from the levels of CSO, Director, VP, Head, Senior Investigator, Manager, Principal Scientist, Team Leader, Group leaders, Clinicians, Professor, Assistant professors. The early registration of the conference is now available on the website or you can write to Amit Shelke at for more details on speakers, sessions and presentations along with registration deta ...

News Release: Next Gen Immuno-Oncology Congress-USA will discuss advancements in cancer immunotherapy, clinical development of immune checkpoint inhibitors and neoantigen-based immunotherapy.
Submitted on: March 05, 2018 01:00:51 PM
Submitted by: Shardul Oza
On behalf of: